Radiolabeled Antibody Therapy of Human B Cell Lymphomas
Modern chemotherapy regimens are capable of curing the majority of patients with newly diagnosed diffuse aggressive lymphomas1, but few patients with low-grade lymphomas or relapsed aggressive lymphomas can be cured with conventional therapy. High dose chemoradiotherapy in conjunction with marrow transplantation affords long term disease-free survival for approximately 25% of such patients2,3, but toxicity is formidable and post-transplant relapse and treatment-related complications result in the death of most such patients. Targeted radiotherapy using radiolabeled antibodies (RAb) offers a potentially effective new approach for refractory malignancies as demonstrated by a variety of animal and human studies4–13. In this report we summarize our experience administering radiolabeled anti-B cell antibodies to patients with refractory non-Hodgkin’s lymphomas in a phase I dose escalation trial.
KeywordsAggressive Lymphoma Massive Splenomegaly Autologous Marrow Radiation Therapy Oncology Group Study Refractory Malignancy
Unable to display preview. Download preview PDF.
- 1.P. Klimo. Chemotherapy for aggressive non-Hodgkin’s lymphomas, in “Cancer: Principles and Practice of Oncology-Update 2 (no. 9),” pp. 1–12, De Vita VT, Hellman S, Rosenberg SA, eds., Lippincott, Philadelphia (1988).Google Scholar
- 3.F. B. Petersen, F. R. Appelbaum, R. Hill, L. D. Fisher, C. L. Bigelow, J. E. Sanders, K. M. Sullivan, W. I. Bensinger, R. P. Witherspoon, R. Storb, R. A. Clift, A. Fefer, O. W. Press, P. L. Weiden, J. Singer, E. D. Thomas, and C. D. Buckner, Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle, J. Clin. Oncol. 8: 638–647 (1990).PubMedGoogle Scholar
- 6.F. R. Appelbaum, P. Brown, and B. Sandmaier, Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation, Blood (in press).Google Scholar
- 10.S. DeNardo, G. DeNardo, and L. O’Grady, Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody, Antibod. Immunoconjugates Radiopharmaceut. 1: 17–33 (1988).Google Scholar
- 13.O. W. Press, J. Eary, C. C. Badger, F. A. Appelbaum, P. J. Martin, R. Levy, R. Miller, S. Brown, W. B. Nelp, K. A. Krohn, D. Fisher, K. De Santes, B. Porter, P. Kidd, E. D. Thomas, and I. D. Bernstein, Treatment of patients with refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody, J. Clin. Onc. 7: 1027–1038 (1989).Google Scholar
- 15.Society of Nuclear Medicine: MIRD Primer for absorbed dose calculation, Washington D.C., Society of Nuclear Medicine (1988).Google Scholar
- 16.J. A. Bianco, B. Sandmaier, P. A. Brown, C. Badger, I. Bernstein, J. Eary, L. Durack, F. Schuening, R. Storb, and F. Appelbaum, Specific marrow localization of an I-131-labeled anti-myeloid antibody in normal dogs: effects of a “cold” antibody pretreatment dose on marrow localization, Exp. Hematol. 17: 929–934 (1989).PubMedGoogle Scholar